{"id":742140,"date":"2011-02-28T00:01:00","date_gmt":"2011-02-28T00:01:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/"},"modified":"2026-08-10T13:01:18","modified_gmt":"2026-08-10T17:01:18","slug":"fujifilm-to-acquire-merck-biomanufacturing-network","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/","title":{"rendered":"Fujifilm to Acquire Merck Biomanufacturing Network"},"content":{"rendered":"<p class=\"bwalignc\">       Fujifilm Purchases Merck Contract Manufacturing and Service        Subsidiaries Diosynth and MSD Billingham     <\/p>\n<p>\n      FUJIFILM Corporation and Merck (NYSE:MRK), known as MSD outside the<br \/>\n      United States and Canada, today announced they have entered into a<br \/>\n      definitive agreement by which Fujifilm will acquire the Merck<br \/>\n      BioManufacturing Network, a leading provider of contract manufacturing<br \/>\n      and development services for the biopharmaceutical industry and wholly<br \/>\n      owned by Merck.\n    <\/p>\n<p>\n      &#8220;Fujifilm continues to build upon its ongoing commitment to delivering<br \/>\n      pharmaceutical business,&#8221; said Shigetaka Komori, president and chief<br \/>\n      executive officer of FUJIFILM Corporation. &#8220;This acquisition provides an<br \/>\n      important addition to our pharmaceutical business with diverse<br \/>\n      capabilities and technical expertise in production of protein<br \/>\n      therapeutics.&#8221;\n    <\/p>\n<p>\n      Under the terms of the agreement, Fujifilm will purchase all of the<br \/>\n      equity interests in two Merck subsidiaries (Diosynth RTP, LLC and MSD<br \/>\n      Biologics (U.K.) Limited) which together own all assets of the Merck<br \/>\n      BioManufacturing Network comprising facilities located in Research<br \/>\n      Triangle Park, North Carolina (Diosynth RTP, LLC) and Billingham, U.K.<br \/>\n      (MSD Biologics (U.K.) Limited); and including manufacturing contracts;<br \/>\n      business support operations and a highly skilled workforce. As part of<br \/>\n      the agreement with Fujifilm, Merck\/ MSD has committed to certain<br \/>\n      continued development and manufacturing activities with these two<br \/>\n      companies. Financial details of the transaction were not disclosed.\n    <\/p>\n<p>\n      &#8220;When Merck\/ MSD combined its biopharmaceutical manufacturing services<br \/>\n      businesses in the United States and U.K. into the Merck BioManufacturing<br \/>\n      Network, we established one of the world&#8217;s leading biopharmaceutical<br \/>\n      contract manufacturing organizations,&#8221; said Willie A. Deese, executive<br \/>\n      vice president and president, Merck Manufacturing Division. \u201cWith this<br \/>\n      transaction, Merck\/MSD becomes a key customer that will continue to<br \/>\n      benefit from the expertise and experience of the combined businesses in<br \/>\n      biologics development and manufacturing.&#8221;\n    <\/p>\n<p>\n      The effectiveness of the agreement is subject to the expiration or<br \/>\n      earlier termination of the waiting period under the Hart-Scott-Rodino<br \/>\n      Antitrust Improvements Act, if applicable, as well as other customary<br \/>\n      closing conditions.\n    <\/p>\n<p>\n      <b>Merck\/MSD Biomanufacturing Network<\/b>\n    <\/p>\n<p>\n      Merck\/MSD Biomanufacturing Network was formed by the combination of MSD<br \/>\n      Biologics, based in Billingham, U.K. and Diosynth Biotechnology, based<br \/>\n      in Research Triangle Park, North Carolina, U.S.A. Merck BioManufacturing<br \/>\n      Network offers industry-leading cGMP contract manufacturing services for<br \/>\n      recombinant proteins, vaccines and monoclonal antibodies. The combined<br \/>\n      expertise enables customers to improve the cost-effectiveness and<br \/>\n      profitability of new therapies by providing fast-track progress into and<br \/>\n      through their clinical development program, validation and<br \/>\n      commercialization.\n    <\/p>\n<p>\n      <b>About FUJIFILM Corporation<\/b>\n    <\/p>\n<p>\n      FUJIFILM Corporation is one of the major operating companies of FUJIFILM<br \/>\n      Holdings. Since its founding in 1934, the company has built up a wealth<br \/>\n      of advanced technologies in the field of photo imaging, and in line with<br \/>\n      its efforts to become a comprehensive healthcare company, Fujifilm is<br \/>\n      now applying these technologies to the prevention, diagnosis and<br \/>\n      treatment of diseases in the Medical and Life Science fields. Fujifilm<br \/>\n      is also expanding growth in the highly functional materials business,<br \/>\n      including flat panel display materials, and in the graphic systems and<br \/>\n      optical devices businesses.\n    <\/p>\n<p>\n      Fujifilm&#8217;s corporate philosophy is: We will use leading-edge,<br \/>\n      proprietary technologies to provide top-quality products and services<br \/>\n      that contribute to the advancement of culture, science, technology and<br \/>\n      industry, as well as improved health and environmental protection in<br \/>\n      society. Our overarching aim is to help enhance the quality of life of<br \/>\n      people worldwide. Through its corporate philosophy, Fujifilm<br \/>\n      demonstrates its commitment to making a significant contribution to<br \/>\n      society. For more information, please visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.fujifilm.com&amp;esheet=50281537&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.fujifilm.com.&amp;index=1&amp;md5=661057b482a1973ab69e804ad1177980\"><span class=\"bwuline\">http:\/\/www.fujifilm.com<\/span>.<\/a>\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships that<br \/>\n      donate and deliver our products to the people who need them. For more<br \/>\n      information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=50281537&amp;lan=en-US&amp;anchor=www.merck.com.&amp;index=2&amp;md5=b3c8d6043bdb38c06668786586b048de\"><span class=\"bwuline\">www.merck.com<\/span>.<\/a>\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes &#8220;forward-looking statements&#8221; within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company&#8217;s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck&#8217;s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and health care legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck&#8217;s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck&#8217;s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the United States and internationally and the exposure to<br \/>\n      litigation and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck&#8217;s 2009 Annual Report on Form 10-K and the company&#8217;s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC&#8217;s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50281537&amp;lan=en-US&amp;anchor=www.sec.gov%29.&amp;index=3&amp;md5=a67e31a28e103bcde876df4ec55fa41c\"><span class=\"bwuline\">www.sec.gov<\/span>).<\/a>\n    <\/p>\n<p>\n      Photos\/Multimedia Gallery Available: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6627555%26lang%3Den&amp;esheet=50281537&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6627555%26lang%3Den&amp;index=4&amp;md5=d312866f2530017fa5bc3dade5db6430\"><span class=\"bwuline\">http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=6627555&amp;lang=en<\/span><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516007058r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Contacts<br \/>Merck<br \/>Media:<br \/>Ian R. McConnell,        908-423-3046<br \/>or<br \/>Investor:<br \/>Joe Romanelli, 908-423-5088<br \/>or<br \/>Fujifilm<br \/>Media:<br \/>Corporate        Public Relations Division<br \/><a href=\"mailto:pr_pharmaceuticals@fujifilm.co.jp\"><span>pr_pharmaceuticals@fujifilm.co.jp<\/span><\/a><br \/>+81-3-6271-2000     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Fujifilm Purchases Merck Contract Manufacturing and Service Subsidiaries Diosynth and MSD Billingham FUJIFILM Corporation and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceutical industry and wholly owned by Merck. &#8220;Fujifilm continues to build upon its ongoing commitment to delivering pharmaceutical business,&#8221; said Shigetaka Komori, president and chief executive officer of FUJIFILM Corporation. &#8220;This acquisition provides an important addition to our pharmaceutical business with diverse capabilities and technical expertise in production of protein therapeutics.&#8221; Under the terms of the agreement, Fujifilm will purchase all of the equity interests in two Merck subsidiaries (Diosynth RTP, LLC and MSD Biologics (U.K.) Limited) which together own all<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742140","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fujifilm to Acquire Merck Biomanufacturing Network - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fujifilm to Acquire Merck Biomanufacturing Network - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Fujifilm Purchases Merck Contract Manufacturing and Service Subsidiaries Diosynth and MSD Billingham FUJIFILM Corporation and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceutical industry and wholly owned by Merck. &quot;Fujifilm continues to build upon its ongoing commitment to delivering pharmaceutical business,&quot; said Shigetaka Komori, president and chief executive officer of FUJIFILM Corporation. &quot;This acquisition provides an important addition to our pharmaceutical business with diverse capabilities and technical expertise in production of protein therapeutics.&quot; Under the terms of the agreement, Fujifilm will purchase all of the equity interests in two Merck subsidiaries (Diosynth RTP, LLC and MSD Biologics (U.K.) Limited) which together own all\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516007058r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fujifilm-to-acquire-merck-biomanufacturing-network\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fujifilm-to-acquire-merck-biomanufacturing-network\\\/\",\"name\":\"Fujifilm to Acquire Merck Biomanufacturing Network - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fujifilm-to-acquire-merck-biomanufacturing-network\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fujifilm-to-acquire-merck-biomanufacturing-network\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120516007058r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2011-02-28T00:01:00+00:00\",\"dateModified\":\"2026-08-10T17:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fujifilm-to-acquire-merck-biomanufacturing-network\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fujifilm-to-acquire-merck-biomanufacturing-network\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fujifilm-to-acquire-merck-biomanufacturing-network\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120516007058r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120516007058r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/fujifilm-to-acquire-merck-biomanufacturing-network\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fujifilm to Acquire Merck Biomanufacturing Network\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fujifilm to Acquire Merck Biomanufacturing Network - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/","og_locale":"en_US","og_type":"article","og_title":"Fujifilm to Acquire Merck Biomanufacturing Network - Merck.com","og_description":"Fujifilm Purchases Merck Contract Manufacturing and Service Subsidiaries Diosynth and MSD Billingham FUJIFILM Corporation and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceutical industry and wholly owned by Merck. \"Fujifilm continues to build upon its ongoing commitment to delivering pharmaceutical business,\" said Shigetaka Komori, president and chief executive officer of FUJIFILM Corporation. \"This acquisition provides an important addition to our pharmaceutical business with diverse capabilities and technical expertise in production of protein therapeutics.\" Under the terms of the agreement, Fujifilm will purchase all of the equity interests in two Merck subsidiaries (Diosynth RTP, LLC and MSD Biologics (U.K.) Limited) which together own all","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:18+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516007058r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/","name":"Fujifilm to Acquire Merck Biomanufacturing Network - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516007058r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2011-02-28T00:01:00+00:00","dateModified":"2026-08-10T17:01:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516007058r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120516007058r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/fujifilm-to-acquire-merck-biomanufacturing-network\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Fujifilm to Acquire Merck Biomanufacturing Network"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"011737ea-4685-4f42-9a83-83525b69afb6","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Fujifilm-to-Acquire-Merck-Biomanufacturing-Network-2011.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742140","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742140\/revisions"}],"predecessor-version":[{"id":3679276,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742140\/revisions\/3679276"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742140"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742140"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}